Silence Therapeutics (SLN) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

SLN Silence Therapeutics

Watchlist

7.590
+0.130+1.74%

Trading Nov 27 09:44 ET

358.36MMarket Cap-4493P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
BusinesswireNov 26 08:00 ET
Express News | Silence Therapeutics PLC : Jefferies Cuts Target Price to $31 From $38
ReutersNov 21 01:07 ET
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
MT NewswiresNov 20 11:08 ET
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
Zacks Nov 20 10:30 ET
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
BenzingaNov 19 15:34 ET
Silence Therapeutics Weakness After AHA Updates 'Overdone,' Says BMO Capital
TipRanksNov 19 12:55 ET

Comments

Mcsnacks H Tupack

Nov 22 02:52

Top 2 Long Term stocks(3 months)

$Silence Therapeutics (SLN.US)$ Stock rated a buy and with the lowest PT being $31. Had the same dip last year so it will be around February 21 when it reaches its PT.
$Rezolve AI (RZLV.US)$ Alot of short shares sold this month and in September. Reversal should be starting now that it has reached $1.63. First climb will be to 4.70 with that PT being at the end of December. February's PT will be 12.00. Partnerships with Microsoft and Google will push it until they re...

Johnny Mnemonic

Nov 20 14:53

still severely oversold

Johnny Mnemonic

Nov 20 13:29

shorts gonna get burned if they don't get out, there's this much outflow and still pushing, be careful

Stock_Drift

Nov 18 14:13

$Silence Therapeutics (SLN.US)$

Moomoo AI

Feb 3 06:08

Despite strong growth, Silence Therapeutics' high P/S ratio and weak revenue outlook suggest a risk of share price decline. Analysts lack confidence in a business turnaround, indicating potential risk for shareholders and potential investors.

Optimistic Investors Push Silence Therapeutics Plc (NASDAQ:SLN) Shares Up 26% But Growth Is Lacking

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

SLN Silence Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target